Metabolic Research Peptides: A Cluster Overview
Metabolic research peptides are one of the three research clusters Captide Labs organizes its catalog around, grouping the compounds most studied in preclinical models of energy expenditure, fat metabolism, and mitochondrial function. This overview introduces the compounds in the metabolic research peptides cluster — SLU-PP-332, BAM-15, 5-Amino-1MQ, Tesofensine, and Orforglipron — and explains how the capsule-first format relates to the research literature on each. It makes no claims about effects in humans; all compounds discussed are supplied strictly for laboratory and research use only and are not approved for human use by the FDA or other regulatory authorities.
What “metabolic research peptides” refers to
The phrase metabolic research peptides is used here as a research convenience for a group of compounds studied in models of metabolism, energy expenditure, and body composition. It is not a regulatory category, and the group is chemically diverse — some members are peptides in the strict sense, while others are small molecules studied alongside them in the same metabolic research context. What unites them is an overlapping body of preclinical literature around mitochondrial function, fatty acid oxidation, and appetite or energy regulation. As with every cluster, the evidence base is overwhelmingly preclinical, drawn from animal and in vitro studies, with limited human data. Researchers should treat these as research tools whose profiles are defined by laboratory studies, not by established human outcomes.
The compounds in the cluster
SLU-PP-332. A synthetic agonist of the estrogen-related receptors studied as an exercise mimetic. In mouse studies it has been described as inducing an acute aerobic exercise program. One review of the compound reported that SLU-PP-332 administration mimics exercise-induced benefits on whole-body metabolism in mice, including increased energy expenditure and fatty acid oxidation accompanied by decreased fat mass accumulation (ScienceDirect). It is one of the most-searched metabolic research peptides. ScienceDirect
BAM-15. A selective mitochondrial uncoupler studied for its effect on mitochondrial respiration and energy expenditure. A review of the compound describes how BAM15 disrupts the coupling between electron transport and ATP synthesis, dissipating the proton gradient and increasing mitochondrial respiration and energy expenditure (PMC review). It anchors the mitochondrial-uncoupler side of the cluster. nih
5-Amino-1MQ. A small molecule studied as an inhibitor of the enzyme NNMT, investigated in preclinical metabolic models for its role in cellular energy regulation and adipocyte metabolism.
Tesofensine. A compound studied in the context of appetite and energy balance, investigated in preclinical and clinical literature for effects on food intake and body weight.
Orforglipron. A non-peptide oral compound studied as a GLP-1 receptor agonist, investigated in the metabolic and body-weight literature and notable as an orally available member of the cluster.
Why the capsule format fits this cluster
A defining feature of the metabolic research peptides cluster is that several of its compounds are studied specifically in the oral context. SLU-PP-332 is described in the literature as orally active, and Orforglipron is an orally available GLP-1 receptor agonist. That makes the capsule format particularly well aligned with this cluster, since the research questions around several of these compounds concern the oral route directly. The capsule standardizes the quantity of material per unit and removes the reconstitution and liquid-handling steps that vial and spray formats require, reducing a source of handling variability in repeatable research.
This is the niche Captide Labs concentrates on: the capsule format and the body of oral-research literature around these compounds. For how the formats compare in general, see our peptide capsules vs. other formats guide.
Capsule and spray formats within the cluster
Format frames a different set of research variables for each compound. Capsules deliver a standardized fixed quantity per unit with no reconstitution, which suits research designs concerned with the oral route and with repeatable dosing units — a strong fit for the orally studied members of the metabolic research peptides cluster. Sprays present a pre-prepared liquid relevant to mucosal research models. Lyophilized vials give maximum control over concentration but introduce reconstitution and sterile-handling steps where error can enter. Because this cluster includes several compounds whose research literature centers on oral availability, the capsule format is often the natural starting point rather than an afterthought.
How researchers approach the cluster
Researchers working across metabolic research peptides generally select compounds based on the specific pathway and model under study rather than treating the cluster as interchangeable. SLU-PP-332 appears in exercise-mimetic and ERR-signaling research; BAM-15 in mitochondrial-uncoupling and energy-expenditure studies; 5-Amino-1MQ in NNMT-inhibition and adipocyte research; Tesofensine in appetite and energy-balance literature; Orforglipron in GLP-1 receptor research. Matching the compound to the research question is the same principle that applies to format selection — the goal is fit, not familiarity.
Handling and storage across the cluster
Beyond identity and purity, practical handling affects reproducibility when working with metabolic research peptides. Capsules remove the per-use measurement step that powder and vial formats require, which reduces a meaningful source of variability for designs that depend on consistent quantities. Storage should follow supplier specifications and general good practice for research compounds, keeping material sealed and protected from heat, moisture, and light until use. These handling considerations apply across the cluster regardless of which compound is under study.
Regulatory and compliance context
None of the metabolic research peptides in this cluster are approved for human use by the FDA or comparable authorities, and several are explicitly noted in the literature as prohibited in sport by anti-doping bodies. They are supplied for laboratory and research applications only. Anyone sourcing these compounds should understand that their legitimate use is confined to research settings, and that no health, therapeutic, or performance claims can accompany them. This framework is not a limitation on the research value of the compounds; it is the context within which they are legitimately studied and supplied.
Sourcing metabolic research peptides
As with any research compound, the variables that matter most are identity and purity, and those come down to sourcing and analytical testing rather than the format or the cluster label. When evaluating a supplier of metabolic research peptides, look for:
- Third-party analytical testing (e.g. HPLC) confirming identity and purity, with documentation available on request.
- A stated purity specification rather than vague quality claims.
- Clear research-use-only labeling and the absence of health, therapeutic, or performance claims — both a compliance signal and a credibility signal.
Captide Labs supplies the metabolic research cluster — SLU-PP-332, BAM-15, 5-Amino-1MQ, Tesofensine, and Orforglipron — in capsule format, each with third-party testing documentation. Browse the full peptide capsule catalog to see the tissue repair, metabolic, and cognitive research clusters.
All Captide Labs products are intended for laboratory and research use only. They are not for human consumption and are not intended to diagnose, treat, cure, or prevent any disease. The compounds discussed are not approved for human use by the FDA or other regulatory authorities.
